Resistance to trastuzumab: a necessary evil or a temporary challenge?
about
Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells.Neoadjuvant therapy for early-stage breast cancer: the clinical utility of pertuzumabModulation of MicroRNA-194 and cell migration by HER2-targeting trastuzumab in breast cancerThe potential of optical proteomic technologies to individualize prognosis and guide rational treatment for cancer patientsA multiscale systems perspective on cancer, immunotherapy, and Interleukin-12Combinatorial experimental protocols for Erbicin-derived immunoagents and Herceptin.Dissecting GRB7-mediated signals for proliferation and migration in HER2 overexpressing breast tumor cells: GTP-ase rules.Trastuzumab reverses letrozole resistance and amplifies the sensitivity of breast cancer cells to estrogen.Models for prevention and treatment of cancer: problems vs promises.Human anti-ErbB2 immunoagents--immunoRNases and compact antibodies.HER2-HER3 dimer quantification by FLIM-FRET predicts breast cancer metastatic relapse independently of HER2 IHC status.Pnck overexpression in HER-2 gene-amplified breast cancer causes Trastuzumab resistance through a paradoxical PTEN-mediated process.HER2 signaling downregulation by trastuzumab and suppression of the PI3K/Akt pathway: an unexpected effect on TRAIL-induced apoptosis.CD55 and CD59 expression protects HER2-overexpressing breast cancer cells from trastuzumab-induced complement-dependent cytotoxicity.A novel ErbB2 epitope targeted by human antitumor immunoagents
P2860
Q24813543-03330014-CBB4-499D-A4B4-F8CDFFE1A815Q26764879-C6828DB3-30D0-4C02-A3A6-EA538F5F35A4Q28729012-8B4CC874-6755-4313-BCF4-05584D60B78FQ33503737-76407408-0B25-4916-AA4A-C9AF1AD45FCDQ35624686-8403FDBB-315C-4D1E-B489-C6F52152377AQ36610604-D588F37E-D53D-4846-8C3F-F8B8A979B3B2Q36758884-150384A0-1E16-4269-A971-0990CD1CECA5Q37101433-3A1F81CF-3706-4DF2-9B61-837F826E169BQ37356273-6C5B6DCB-05E8-43FE-A100-E07DABC1999FQ37394278-3F164606-5958-4E97-B26B-20409F8D1FA7Q37588232-B14A821A-6242-4229-A9AF-ADB14B3CADB1Q38899532-EB11ED09-2B43-4D57-89D7-EDBF4F83BC36Q40397252-ED9465F5-5C7A-48F1-9DE6-E2D1DC41E1A3Q41612157-94296627-CC21-4886-938A-9FF3CBFBBD73Q57628597-E6B2F8F5-0584-45A3-85AF-F6893D1E7A29
P2860
Resistance to trastuzumab: a necessary evil or a temporary challenge?
description
2002 nî lūn-bûn
@nan
2002 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Resistance to trastuzumab: a necessary evil or a temporary challenge?
@ast
Resistance to trastuzumab: a necessary evil or a temporary challenge?
@en
Resistance to trastuzumab: a necessary evil or a temporary challenge?
@nl
type
label
Resistance to trastuzumab: a necessary evil or a temporary challenge?
@ast
Resistance to trastuzumab: a necessary evil or a temporary challenge?
@en
Resistance to trastuzumab: a necessary evil or a temporary challenge?
@nl
prefLabel
Resistance to trastuzumab: a necessary evil or a temporary challenge?
@ast
Resistance to trastuzumab: a necessary evil or a temporary challenge?
@en
Resistance to trastuzumab: a necessary evil or a temporary challenge?
@nl
P356
P1476
Resistance to trastuzumab: a necessary evil or a temporary challenge?
@en
P2093
Martine J Piccart
Virginie Durbecq
P304
247-57; discussion 258-9
P356
10.3816/CBC.2002.N.028
P407
P577
2002-10-01T00:00:00Z